ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies

DALLAS, March 2, 2010 - ReportsandReports announce to have The Gastrointestinal Market Outlook to
2014: (
www.reportsandreports.com/market-reports/the-gastrointestinal-market-o
utlook-to-2014-market-dynamics-com/) Market dynamics, competitive landscape,
emerging therapies Market Research Report in its store.

(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

Gastrointestinal disorders are quite diverse affecting different parts of
the alimentary tract such as the pancreas, oropharynx, liver and biliary
system and the alimentary canal. Causes of these disorders vary and could
include genetic anomalies, the effect of certain toxins and drugs,
infections, cancer and often unknown causes. Disorders of the
gastrointestinal tract (GIT) are fairly common and occur in people of all
ages. These disorders take up a significant share of the disease burden in
developed economies and the gravity of the problem is further accentuated by
the difficulty that they pose in effective management. GIT therapy area
consists of some indications that can be treated through pharmacologic
interventions, though significant unmet need still exists. These unmet
medical needs are more common for indications such as irritable bowel
syndrome (IBS), Crohn's disease (CD) and ulcerative colitis (UC). An
incomplete understanding of the etiologies of these diseases limits their
effective treatment, leading to misguided treatment and misdiagnosis. A
significant fraction of the drugs used in the GIT therapy area are for the
treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease
(GERD). The therapy area overall, however, reflects significant levels of
genericization with R&D efforts drifting towards novel therapies for Crohn's
disease and inflammatory bowel disease (IBD). In several instances though,
the shift could be out of GIT to the faster growing therapy areas such as
oncology, cardiovascular disorders and autoimmune disorders.

    Scope of this report

    - Epidemiological analysis of the therapy area and forecast prevalence
      over the period 2009-14

    - Forecasts and analysis of the key products in the gastrointestinal
      market over the period 2009-14 across major classes of treatments

    - Detailed analysis across major classes of gastrointestinal treatment
      including immunosuppressants and anti-rheumatic agents

    - Detailed analysis of the clinically differentiated products in the
      gastrointestinal market pipeline and sales forecast of key R&D pipeline
      products in the global gastrointestinal market

Key findings from this report

Growth in the Crohn's disease and ulcerative colitis market is likely to
be driven by self-injectable products. This would lead to the transition of a
significant proportion of patients on Remicade therapy to these products. The
convenience of self-injection would help in driving growth in this category
while facilitating earlier use of drugs. These dynamics have the potential to
fuel growth while expanding the market in these categories.

AstraZeneca has constituted a new company, which will be funded by three
private equity firms, with several of its gastrointestinal programs. This new
biotech venture of the company, called Albireo, has taken up one early stage
clinical program, besides some preclinical programs of the company. The
private equity firms involved are - TVM Capital, Phase4 Ventures and Scottish
Widows Investment Partnership. This new venture of AstraZeneca is a bid
towards streamlining its gastrointestinal development projects in key
indications such as GERD and for line extensions of its market leading
product Nexium.

Many of the top ten players posted a decline in sales over 2007, a fact
indicative of the high degree of genericization in the market. Over all,
drugs indicated for the treatment of ulcer are expected to drag down the
sales of most players. Thus, companies that have maintained a more diverse
drug class portfolio are expected to gain more in the long run.

    Use this report to:

    - Develop insights into patient potential with the report's coverage of
      the therapy area and top ten leading gastrointestinal players today.

    - Quickly understand how recent events are affecting the performance of
      major products, and how leading players are confronting competitive
      challenges in the gastrointestinal marketplace.

    - Gain up-to-date market intelligence across the gastrointestinal
      category and understand the major issues affecting key pharmaceutical
      marketers.

    - Understand which drug classes have the greatest potential to drive
      gastrointestinal franchise growth, and how pharmaceutical companies are
      attempting to capitalize these market opportunities.

    - Compare the franchises of leading pharmaceutical companies across key
      therapeutic classes and understand how market share of leading
      companies will evolve over the next six years.

    Related Reports

    - Abbott Laboratories-Deals & Alliances Report
    - Abbott Laboratories-Detailed Product Pipeline
    - Abbott Laboratories-IT Sales Opportunities-2009
    - Abbott Laboratories: PharmaVitae Profile
    - Acorda Therapeutics, Inc.-Deals & Alliances Report

About Us

ReportsandReports, (www.reportsandreports.com/) comprising of an
online library of 10,000 reports, in-depth market research studies of over
5000 micro markets, and 25 industry specific websites. Our client list boasts
of almost all well-known publishers of such reports across the globe. We, as
a third party reseller of market research reports employ number of marketing
tools such as press releases, email-marketing and effective search engine
optimization technique to drive revenues for our clients. We also provide
24/7 online and offline support to our customers.

    Contact:
    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    Email: sales@reportsandreports.com

    www.reportsandreports.com/

Contact: Ms. Sunita, 7557 Rambler road, Suite 727, Dallas, TX 75231, Tel: +1-888-989-8004, Email: sales at reportsandreports.com